{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-021864","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.177201+00:00","generated_at":"2026-06-01T07:24:19.545737+00:00","sec_items":["1.01","8.01","2.03","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Celcuity secures up to $180M debt financing, plans Phase 3 gedatolisib trial in HR+/HER2- breast cancer","bullets":["New A&R Loan Agreement with Innovatus and Oxford provides up to $180M; $100M funded including $61.7M new borrowings.","Loan matures May 2029; interest-only for 36 months (extendable to 48 months) at Prime + 2.85% (floor 7.75%).","Phase 3 VIKTORIA-2 trial to enroll ~638 HR+/HER2- ABC patients; first patient expected Q2 2025.","Trial design allows investigator choice of ribociclib or palbociclib; FDA concurred in Type C meeting.","Warrants issued equal to 2.5% of each tranche; Innovatus can convert up to 20% of Term A at $10.00/share."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-021864","json":"https://secwatch.observer/filing/0001493152-24-021864.json","markdown":"https://secwatch.observer/filing/0001493152-24-021864.md","text":"https://secwatch.observer/filing/0001493152-24-021864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224021864/0001493152-24-021864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224021864/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:24:19.545737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}